BMKDF (Biomark Diagnostics) Accumulated Depreciation: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMKDF Biomark Diagnostics Inc BMKDF
24 GF Score
Price $0.37
! 3 Warning Signs
View Full Analysis

What is Biomark Diagnostics Accumulated Depreciation?

Biomark Diagnostics BMKDF 24 Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus rates BMKDF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Biomark Diagnostics's annual accumulated depreciation increased from Mar. 2024 ($-0.02 Mil) to Mar. 2025 ($-0.03 Mil) and increased from Mar. 2025 ($-0.03 Mil) to Mar. 2026 ($-0.05 Mil).

Biomark Diagnostics Accumulated Depreciation Related Terms

Biomark Diagnostics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics Accumulated Depreciation Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.01 -0.02 -0.03 -0.05

Biomark Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BMKDF
24GF Score
Biomark Diagnostics Inc BMKDF
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Biomark Diagnostics (BMKDF) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' Accumulated Depreciation too high?
Biomark Diagnostics' current Accumulated Depreciation is $0.00 Mil. Overall, Biomark Diagnostics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Accumulated Depreciation compare to TMO and DHR?
Biomark Diagnostics' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Diagnostics & Research company?
A good Accumulated Depreciation depends on the Medical Diagnostics & Research industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (BMKDF) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. Biomark Diagnostics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Biomark Diagnostics (BMKDF), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Other Exchanges 20B:GermanyBUX:Canada
Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
24GF Score

Get the complete analysis for BMKDF

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price